Identification
- Summary
Neomycin is an aminoglycoside antibiotic agent used orally and topically to treat a wide variety of infections in the body.
- Brand Names
- Casporyn HC, Cortisporin, Cortisporin-TC, Dioptrol, Diosporin, Diphen, Maxitrol, Neo-polycin, Neo-polycin HC, Neo-synalar, Neosporin Ointment, Neosporin Plus Maximum Strength, Neosporin Plus Maximum Strength Cream, Neosporin Solution, Procomycin, Statrol, Triple Antibiotic, Viaderm Kc
- Generic Name
- Neomycin
- DrugBank Accession Number
- DB00994
- Background
Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of Streptomyces fradiae.5 Neomycin is a complex comprised of three components, neomycin A, B, and C.2 Neomycin B, also known as framycetin, is the most active component of the complex and neomycin C is the isomer of neomycin B, making these two stereoisomers the active components of neomycin.1,2 Neomycin A, or neamine, is a moiety that conjoins two molecules of neomycin B and C together.1 Neomycin is active against both gram-positive and gram-negative organisms and mediates its pharmacological action by binding to bacterial ribosomes and inhibiting protein synthesis, which is crucial for the survival of bacteria.9
Neomycin sulfate is the most common form for pharmaceutical preparations; because the compound is a complex, the amount of neomycin in products is measured in units.2 Neomycin sulfate as monotherapy is available in an oral solution for adjunct use in the treatment of hepatic coma.5 It is also used in combination with polymyxin B sulfates and hydrocortisone in otic suspensions for use in the treatment of bacterial infections in the external auditory canal, including infections caused by medical procedures in the ear.6 Neomycin is also used in combination with polymyxin B sulfates and dexamethasone in ophthalmic preparations for use in the treatment of inflammatory conditions and infections in the eye.7 Neomycin is also available in over-the-counter topical products to prevent minor skin infections.
- Type
- Small Molecule
- Groups
- Approved, Vet approved
- Synonyms
- Fradiomycin
- Kaomycine
- Neomicina
- Neomycin
- Vonamycin
- External IDs
- Caswell No. 595
- USAF CB-19
Pharmacology
- Indication
Oral neomycin sulfate is indicated as an adjunctive therapy in hepatic coma (portal-system encephalopathy) by reducing ammonia-forming bacteria in the intestinal tract. It is strongly recommended that oral neomycin is only used in infections that are proven or strongly suspected to be caused by susceptible bacteria to reduce the risk of the development of drug-resistant bacteria.5
Neomycin, in combination with polymyxin B sulfates and hydrocortisone in otic suspensions, is used in the treatment of superficial bacterial infections of the external auditory canal caused by organisms susceptible to the antibiotics. This otic formulation is also used in the treatment of infections of mastoidectomy and fenestration cavities caused by organisms susceptible to the antibiotics.6
The ophthalmic solution containing neomycin in combination with polymyxin B sulfates and dexamethasone is used to treat steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists.7
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Acne pustular Combination Product in combination with: Beclomethasone dipropionate (DB00394) •••••••••••• •••••• ••••••• •••••••• Used in combination to treat Allergic contact dermatitis Combination Product in combination with: Beclomethasone dipropionate (DB00394) •••••••••••• •••••• ••••••• •••••••• Used in combination to treat Allergy skin Combination Product in combination with: Prednisolone (DB00860) •••••••••••• ••••• Used in combination to treat Atopic dermatitis (ad) Combination Product in combination with: Flumethasone (DB00663) •••••••••••• •••••••• Used in combination to treat Atopic dermatitis (ad) Combination Product in combination with: Dexamethasone (DB01234) •••••••••••• ••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Neomycin mediates its bactericidal action by inhibiting bacterial protein synthesis, thereby suppressing the growth and survival of susceptible bacteria. Following oral administration, the duration of bactericidal activity of neomycin ranged from 48 to 72 hours.5 By decreasing colonic bacteria that produce ammonia, neomycin was shown to be effective as an adjunctive therapy in hepatic coma to improve neurologic symptoms.5,9
Neomycin is active against both gram positive and gram negative organisms, including the major E. coli species resident in the colon as well as the enteropathogenic forms of E. coli.9 It is also active against Klebsiella-Enterobacter group.5 Resistant strains of E. coli, Klebsiella and Proteus spp. may emerge from neomycin therapy.2 Neomycin has no antifungal activity and has some activity against some protozoa.1
- Mechanism of action
Like other aminoglycoside antibiotic drugs, neomycin inhibits bacterial ribosomes by binding to the 30S ribosomal subunit of susceptible bacteria and disrupting the translational machinery of bacterial protein synthesis.3,4 Bacterial translation is normally initiated by the mRNA binding to the 30S ribosomal subunit and subsequent binding with 50S subunit for elongation.4
Target Actions Organism A30S ribosomal protein S12 inhibitorEscherichia coli (strain K12) A16S ribosomal RNA inhibitorEnteric bacteria and other eubacteria NExtracellular calcium-sensing receptor Not Available Humans - Absorption
Neomycin is poorly absorbed from the gastrointestinal tract. Gastrointestinal absorption of the drug may be increased if inflammatory or ulcerative gastrointestinal disease is present.5
- Volume of distribution
The small fraction of absorbed neomycin is rapidly distributed in the tissues. The amount of systemically absorbed neomycin is reported to increase cumulatively with each repeated dose administered until a steady state is reached.5
- Protein binding
Findings from protein binding studies suggest low protein binding profile for neomycin sulfate, which can range from 0-30% depending on test methods.5
- Metabolism
There is limited information on the metabolism of neomycin, as there is limited systemic absorption following drug administration. Metabolism is deemed to be negligible.
- Route of elimination
The small absorbed fraction of neomycin is excreted by the kidney. The unabsorbed portion of the drug is excreted unchanged in the feces.5
- Half-life
There is limited information on the half-life of neomycin.
- Clearance
There is limited information on the clearance rate of neomycin.
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
The oral LD50 of neomycin sulfate in mouse is > 8 g/kg. The subcutaneous LD50 is 200 mg/kg in rat and 190 mg/kg in mouse. The intraperitoneal LD50 in mouse is 305 mg/kg. The oral Lowest published toxic dose (TDLo) in woman is 12600 mg/kg/7D.8
Because of low absorption, acute overdosage from oral neomycin is not likely to occur. However, prolonged administration of neomycin should be avoided because of the possibility of some systemic absorption and the risk of neurotoxicity, ototoxicity, and/or nephrotoxicity. Hemodialysis will remove neomycin from the blood. While nephrotoxicity and ototoxicity have been reported in otherwise patients without compromised renal function, the risk for developing these toxicities is increased in patients with renal impairment.9 Like other aminoglycosides, neomycin may cause fetal harm and total irreversible bilateral congenital deafness when administered in pregnant women.5
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Abacavir may decrease the excretion rate of Neomycin which could result in a higher serum level. Acarbose The metabolism of Acarbose can be decreased when combined with Neomycin. Aceclofenac The risk or severity of nephrotoxicity can be increased when Aceclofenac is combined with Neomycin. Acemetacin The risk or severity of nephrotoxicity can be increased when Acemetacin is combined with Neomycin. Acenocoumarol The risk or severity of bleeding can be increased when Neomycin is combined with Acenocoumarol. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Neomycin palmitate 3I9J454G9F 55298-68-5 Not applicable Neomycin sulfate 057Y626693 1405-10-3 Not applicable - Product Images
- International/Other Brands
- Myacyne / Mycifradin / Myciguent / Neo-Rx / Neobiotic / Nivemycin
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Mycifradin Sulfate Oral Solution Solution 125 mg / 5 mL Oral Pharmacia & Upjohn Inc 1957-12-31 2000-08-02 Canada 
Mycifradin Sulfate Tablets 0.5 Gm Tablet 500 mg / tab Oral Pharmacia & Upjohn Inc 1953-12-31 2000-08-02 Canada Myciguent Ointment Ointment .5 % Topical Upjohn 1951-12-31 1998-08-12 Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Neo-Fradin Solution 87.5 mg/5mL Oral X Gen Pharmaceuticals, Inc. 2002-05-23 2012-12-31 US 
Neomycin Sulfate Tablet 500 mg/1 Oral Lannett Company, Inc. 2016-06-10 Not applicable US Neomycin Sulfate Tablet 500 mg/1 Oral Eci Pharmaceuticals Llc 2016-01-16 2016-07-10 US Neomycin Sulfate Tablet 500 mg/1 Oral Chartwell Rx, Llc 2016-06-10 Not applicable US Neomycin Sulfate Tablet 500 mg/1 Oral Golden State Medical Supply, Inc. 2011-01-03 2016-03-31 US 
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Antibiotic Ointment 3.5 mg/1g Topical Pro Mex Llc 2013-12-05 Not applicable US Antibiotic Ointment 3.5 mg/1g Topical Kareway Product, Inc. 2011-08-11 Not applicable US Antibiotic Ointment 3.5 mg/1g Topical Morales Distributors, Inc. 2012-09-25 Not applicable US Antibiotic Ointment 3.5 mg/1g Topical Total Resources International 2019-10-07 Not applicable US Antibiotic Ointment Ointment 3.5 mg/1g Topical Neopharm Co., Ltd 2010-08-26 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image 0.9g Triple Antibiotic Neomycin sulfate (0.0035 g/1g) + Bacitracin zinc (400 [USP'U]/1g) + Polymyxin B sulfate (5000 [USP'U]/1g) Ointment Topical Sled Distribution, LLC 2022-03-24 Not applicable US 10 Person ANSI Neomycin sulfate (5 mg/1g) + Acetaminophen (325 mg/1) + Acetylsalicylic acid (325 mg/1) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (0.13 g/100g) + Benzalkonium chloride (0.40 mL/100mL) + Benzocaine (6 mL/100mL) + Ethanol (60 mL/100mL) + Ibuprofen (200 mg/1) + Lidocaine (0.5 1/100g) + Polymyxin B sulfate (5000 [iU]/1g) + Water (98.6 mL/100mL) Kit Ophthalmic; Oral; Topical Genuine First Aid 2010-04-24 Not applicable US 25 Person ANSI Neomycin sulfate (5 mg/1g) + Acetaminophen (325 mg/1) + Acetylsalicylic acid (325 mg/1) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (0.13 g/100g) + Benzalkonium chloride (0.40 mL/100mL) + Benzocaine (6 mL/100mL) + Ethanol (60 mL/100mL) + Ethanol (62 g/100g) + Ibuprofen (200 mg/1) + Isopropyl alcohol (70 mL/100mL) + Lidocaine (0.5 g/100g) + Polymyxin B sulfate (5000 [iU]/1g) + Water (98.6 mL/100mL) Kit Ophthalmic; Oral; Topical Genuine First Aid 2010-04-25 Not applicable US 4017 First Aid Kit Neomycin sulfate (3.5 mg/1g) + Acetaminophen (325 mg/1) + Benzalkonium chloride (0.13 g/100g) + Benzalkonium chloride (1.3 mg/1mL) + Ethanol (0.5 mL/1mL) + Lidocaine hydrochloride (20 mg/1mL) + Lidocaine hydrochloride (0.5 g/100g) + Water (98.6 mL/100mL) Cream; Kit; Liquid; Ointment; Swab; Tablet Ophthalmic; Oral; Topical Honeywell Safety Products USA, Inc 2018-10-18 Not applicable US 4022 First Aid Kit Neomycin sulfate (3.5 mg/1g) + Acetaminophen (325 mg/1) + Benzalkonium chloride (0.13 g/100g) + Benzalkonium chloride (1.3 mg/1mL) + Ethanol (0.5 mL/1mL) + Lidocaine hydrochloride (20 mg/1mL) + Lidocaine hydrochloride (0.5 g/100g) + Water (98.6 mL/100mL) Cream; Kit; Liquid; Ointment; Swab; Tablet Ophthalmic; Oral; Topical Honeywell Safety Products USA, Inc 2018-10-18 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image 4017 First Aid Kit Neomycin sulfate (3.5 mg/1g) + Acetaminophen (325 mg/1) + Benzalkonium chloride (0.13 g/100g) + Benzalkonium chloride (1.3 mg/1mL) + Ethanol (0.5 mL/1mL) + Lidocaine hydrochloride (20 mg/1mL) + Lidocaine hydrochloride (0.5 g/100g) + Water (98.6 mL/100mL) Cream; Kit; Liquid; Ointment; Swab; Tablet Ophthalmic; Oral; Topical Honeywell Safety Products USA, Inc 2018-10-18 Not applicable US 4022 First Aid Kit Neomycin sulfate (3.5 mg/1g) + Acetaminophen (325 mg/1) + Benzalkonium chloride (0.13 g/100g) + Benzalkonium chloride (1.3 mg/1mL) + Ethanol (0.5 mL/1mL) + Lidocaine hydrochloride (20 mg/1mL) + Lidocaine hydrochloride (0.5 g/100g) + Water (98.6 mL/100mL) Cream; Kit; Liquid; Ointment; Swab; Tablet Ophthalmic; Oral; Topical Honeywell Safety Products USA, Inc 2018-10-18 Not applicable US 4032 First Aid Kit Neomycin sulfate (3.5 mg/1g) + Acetylsalicylic acid (325 mg/1) + Ammonia (0.045 g/0.3mL) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (1.3 mg/1mL) + Lidocaine hydrochloride (24.64 mg/1mL) + Polymyxin B sulfate (5000 [iU]/1g) + Water (98.6 mL/100mL) Inhalant; Kit; Liquid; Ointment; Spray; Tablet Ophthalmic; Oral; Respiratory (inhalation); Topical Honeywell Safety Products USA, Inc 2018-10-18 Not applicable US 4042 First Aid Kit Neomycin sulfate (3.5 mg/1g) + Bacitracin zinc (400 [iU]/1g) + Benzalkonium chloride (0.13 g/100g) + Lidocaine hydrochloride (0.5 g/100g) + Polymyxin B sulfate (5000 [iU]/1g) + Povidone-iodine (10 mg/1mL) Kit Topical Honeywell Safety Products USA, Inc 2018-11-21 2019-10-18 US 4044 First Aid Kit Neomycin sulfate (3.5 mg/1g) + Benzalkonium chloride (0.13 g/100g) + Lidocaine hydrochloride (0.5 g/100g) + Povidone-iodine (10 mg/1mL) Kit Topical Honeywell Safety Products USA, Inc 2018-11-21 2019-10-18 US
Categories
- ATC Codes
- A07AA51 — Neomycin, combinations
- A07AA — Antibiotics
- A07A — INTESTINAL ANTIINFECTIVES
- A07 — ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
- A — ALIMENTARY TRACT AND METABOLISM
- J01GB — Other aminoglycosides
- J01G — AMINOGLYCOSIDE ANTIBACTERIALS
- J01 — ANTIBACTERIALS FOR SYSTEMIC USE
- J — ANTIINFECTIVES FOR SYSTEMIC USE
- D06AX — Other antibiotics for topical use
- D06A — ANTIBIOTICS FOR TOPICAL USE
- D06 — ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE
- D — DERMATOLOGICALS
- S03AA — Antiinfectives
- S03A — ANTIINFECTIVES
- S03 — OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS
- S — SENSORY ORGANS
- A01AB — Antiinfectives and antiseptics for local oral treatment
- A01A — STOMATOLOGICAL PREPARATIONS
- A01 — STOMATOLOGICAL PREPARATIONS
- A — ALIMENTARY TRACT AND METABOLISM
- A07AA — Antibiotics
- A07A — INTESTINAL ANTIINFECTIVES
- A07 — ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
- A — ALIMENTARY TRACT AND METABOLISM
- B05CA — Antiinfectives
- B05C — IRRIGATING SOLUTIONS
- B05 — BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
- B — BLOOD AND BLOOD FORMING ORGANS
- Drug Categories
- Agents that produce neuromuscular block (indirect)
- Alimentary Tract and Metabolism
- Aminoglycoside Antibacterials
- Anti-Bacterial Agents
- Anti-Infective Agents
- Antibacterials for Systemic Use
- Antibiotics for Topical Use
- Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents
- Antiinfectives and Antiseptics for Local Oral Treatment
- Antiinfectives for Systemic Use
- Blood and Blood Forming Organs
- Blood Substitutes and Perfusion Solutions
- Carbohydrates
- Dermatologicals
- Drugs that are Mainly Renally Excreted
- Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index
- Enzyme Inhibitors
- Glycosides
- Intestinal Antiinfectives
- Irrigating Solutions
- Narrow Therapeutic Index Drugs
- Nephrotoxic agents
- Neurotoxic agents
- Ophthalmological and Otological Preparations
- Ophthalmologicals
- Otologicals
- Ototoxic agents
- Protein Synthesis Inhibitors
- Sensory Organs
- Stomatological Preparations
- Throat Preparations
- Classification
- Not classified
- Affected organisms
- Enteric bacteria and other eubacteria
- Pseudomonas aeruginosa
- Haemophilus influenzae
- Escherichia coli
- Klebsiella
- Enterobacter
- Bacteroides
- Enterobacter spp.
Chemical Identifiers
- UNII
- I16QD7X297
- CAS number
- 1404-04-2
References
- Synthesis Reference
Jaehoon Yu, Jongkook Lee, Miyun Kwon, Ae Pae, Hun Koh, "Heterodimeric conjugates of neomycin-oxazolidinone, their preparation and their use." U.S. Patent US20050222055, issued October 06, 2005.
US20050222055- General References
- Lechevalier HA: The 25 years of neomycin. CRC Crit Rev Microbiol. 1975 May;3(4):359-97. [Article]
- Macdonald RH, Beck M: Neomycin: a review with particular reference to dermatological usage. Clin Exp Dermatol. 1983 May;8(3):249-58. doi: 10.1111/j.1365-2230.1983.tb01777.x. [Article]
- Dlugosz M, Trylska J: Aminoglycoside association pathways with the 30S ribosomal subunit. J Phys Chem B. 2009 May 21;113(20):7322-30. doi: 10.1021/jp8112914. [Article]
- 49,50. (2012). In Rang and Dale's Pharmacology (7th ed., pp. 63-). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8]
- FDA Approved Drug Products: Neo-Fradin (Neomycin Sulfate) Oral Solution [Link]
- FDA Approved Drug Products: Casporyn Neomycin Sulfate, Polymixin B Sulfate, and Hydrocortisone Otic Drops [Link]
- FDA Approved Drug Products: Maxitrol Neomycin, Polymyxin B, and Dexamethasone Ophthalmic Suspension [Link]
- Cayman Chemical: Neomycin sulfate Safety Data Sheet [Link]
- Neomycin - LiverTox - NCBI Bookshelf [Link]
- Neomycin Opthalmic FDA Label [File]
- Neomycin Irrigation Solution FDA Label [File]
- Neomycin Otic FDA Label [File]
- Neomycin Tablet FDA Label [File]
- External Links
- FDA label
- Download (169 KB)
- MSDS
- Download (72.9 KB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Active Not Recruiting Prevention Surgery, Colorectal 1 4 Completed Basic Science Rabies Human 1 4 Completed Prevention Urinary Tract Infection 1 4 Completed Treatment Allergic Reaction 1 4 Completed Treatment Vaginal Inflammation 1
Pharmacoeconomics
- Manufacturers
- X gen pharmaceuticals inc
- Pharmacia and upjohn co
- Pfizer laboratories div pfizer inc
- Bristol myers squibb co
- Lannett co inc
- Eli lilly and co
- Oman pharmaceutical products co llc
- Roxane laboratories inc
- Sandoz inc
- Teva pharmaceuticals usa inc
- Packagers
- Akorn Inc.
- Amend
- Bausch & Lomb Inc.
- Dispensing Solutions
- Draxis Specialty Pharmaceuticals Inc.
- Hi Tech Pharmacal Co. Inc.
- Major Pharmaceuticals
- Murfreesboro Pharmaceutical Nursing Supply
- Nucare Pharmaceuticals Inc.
- Pharmedix
- Physicians Total Care Inc.
- Southwood Pharmaceuticals
- Teva Pharmaceutical Industries Ltd.
- UDL Laboratories
- X-Gen Pharmaceuticals
- Dosage Forms
Form Route Strength Inhalant; kit; liquid; ointment; spray; tablet Ophthalmic; Oral; Respiratory (inhalation); Topical Gel; inhalant; kit; liquid; ointment Ophthalmic; Respiratory (inhalation); Topical Kit; liquid; ointment; swab Ophthalmic; Topical Cream; kit; liquid; ointment; swab; tablet Ophthalmic; Oral; Topical Cream; kit; liquid; ointment; swab Ophthalmic; Topical Kit; liquid; ointment; spray; swab; tablet Ophthalmic; Oral; Topical Kit; liquid; lozenge; ointment; spray; swab; tablet Ophthalmic; Oral; Topical Kit Ophthalmic; Oral; Respiratory (inhalation); Topical Gel; inhalant; kit; liquid; ointment; swab Ophthalmic; Respiratory (inhalation); Topical Gel; kit; liquid; ointment; swab Ophthalmic; Topical Kit Ophthalmic; Respiratory (inhalation); Topical Kit Oral; Respiratory (inhalation); Topical Kit Respiratory (inhalation); Topical Inhalant; kit; liquid; ointment; spray; swab Ophthalmic; Respiratory (inhalation); Topical Cream; kit; liquid; ointment; spray; tablet Ophthalmic; Oral; Topical Cream; kit; liquid; ointment; swab; tablet Oral; Topical Kit; liquid; ointment; tablet Ophthalmic; Oral; Topical Inhalant; kit; liquid; ointment; spray; swab; tablet Ophthalmic; Oral; Respiratory (inhalation); Topical Cream; kit; liquid; ointment; swab Topical Gel; kit; ointment; swab Topical Cream; kit; ointment; swab Topical Gel; kit; liquid; ointment Ophthalmic; Topical Kit; liquid; ointment; swab; tablet Ophthalmic; Oral; Topical Gel; kit; liquid; ointment; solution; swab Ophthalmic; Topical Kit; liquid; ointment; swab Topical Gel; kit; liquid; ointment Topical Gel; kit; liquid; ointment; swab Topical Kit; liquid; ointment; spray; swab Ophthalmic; Topical Cream; gel; kit; liquid; ointment; swab Ophthalmic; Topical Cream; kit; liquid; ointment Topical Kit; liquid; ointment; swab; tablet Oral; Topical Kit; liquid; ointment; spray; tablet Ophthalmic; Oral; Topical Cream; gel; kit; liquid; ointment; spray; swab Ophthalmic; Topical Cream; kit; liquid; ointment; spray; swab Ophthalmic; Topical Kit; liquid; ointment Topical Gel; kit; liquid; ointment; swab; tablet Oral; Topical Kit; liquid; ointment Ophthalmic; Topical Kit Irrigation; Ophthalmic; Respiratory (inhalation); Topical Cream; irrigant; kit; liquid; ointment; swab Irrigation; Ophthalmic; Topical Kit Irrigation; Oral; Respiratory (inhalation); Topical Kit Irrigation; Ophthalmic; Oral; Respiratory (inhalation); Topical Ointment Nasal Kit Oral; Topical Kit Topical Solution Other Solution / drops Oral Ointment Topical 3.5 mg/1g Ointment Cutaneous Cream Topical 5 mg/0.9g Ointment Topical 250 iu/g Solution Nasal Syrup Oral Kit Electro-osmosis Cloth; kit; ointment; swab Topical Cream Topical 5 MG/1MG Cream Cutaneous Cream Topical Solution Auricular (otic) Suspension Topical Kit Oral Solution Conjunctival; Ophthalmic Cream Topical 1 g Liquid Auricular (otic); Ophthalmic Solution / drops Auricular (otic); Ophthalmic Ointment Ophthalmic; Topical Cream; kit; liquid; ointment; tablet; tablet, chewable; tablet, film coated Oral; Topical Ointment Tablet Oral Kit Ophthalmic; Topical Liquid Topical Solution Auricular (otic); Topical Kit Ophthalmic; Oral; Topical Cream; kit; tablet, film coated Oral; Topical Cream Cloth; cream; gel; kit; ointment; solution Ophthalmic; Topical Kit Ophthalmic Stick Topical Suspension Conjunctival; Ophthalmic 1 mg Lotion Cutaneous Solution Topical Solution Oral 125 mg / 5 mL Tablet Oral 500 mg / tab Ointment Topical .5 % Cream Topical 0.5 % Powder Topical Suspension Conjunctival; Intraocular; Ophthalmic Cream Topical 0.1 % w/w Suspension Auricular (otic); Ophthalmic Cream Topical 1 g/100g Solution Oral 87.5 mg/5mL Cream Topical 1 % w/w Lotion Topical Lotion Topical 100 mg/ml Solution Intraocular; Ophthalmic Powder, for solution Oral Irrigant Irrigation Solution Irrigation Ointment Ophthalmic Suspension Ophthalmic Solution / drops Ophthalmic Solution / drops Auricular (otic) Suspension / drops Auricular (otic) Suspension / drops Ophthalmic Suspension / drops Topical Powder Not applicable 1 g/1g Tablet Oral 350 mg/1 Tablet Oral 500 mg/1 Cream Topical Solution Auricular (otic); Ophthalmic Solution Urethral Kit; ointment Topical Cream Topical 0.5 % W/W Powder Oral Ointment Conjunctival; Ophthalmic Gel Topical Ointment Auricular (otic) Tablet Oral Suspension Auricular (otic) Solution Ophthalmic 1.3 mg Solution Auricular (otic) 0.1 g/100ml Capsule Vaginal Capsule Vaginal 35000 iu Gel Topical 0.5 g/100g Gel Topical 5 mg/100g Ointment Topical 0.5 g/100g Ointment Rectal Suppository Rectal Cream Cutaneous 2.000 g Cloth; kit; ointment Topical Ointment Topical 0.556 g/100g Ointment Topical Solution Ophthalmic Jelly; kit; ointment Topical Kit Cutaneous Suspension Conjunctival; Ophthalmic Swab Topical Cream Topical 40 mg Spray Cutaneous Ointment Topical 0.5 g Lozenge Oral Tablet Oral 350 mg Liquid Auricular (otic) Suspension Oral Liquid Ophthalmic Tablet - Prices
Unit description Cost Unit Neomycin Sulfate 500 mg tablet 1.39USD tablet Neomycin 500 mg tablet 1.25USD tablet Neomycin sulfate powder 0.84USD g Neo-fradin 125 mg/5 ml soln 0.12USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.8617 Blood Brain Barrier - 0.9659 Caco-2 permeable - 0.7502 P-glycoprotein substrate Non-substrate 0.5164 P-glycoprotein inhibitor I Non-inhibitor 0.8023 P-glycoprotein inhibitor II Non-inhibitor 0.8764 Renal organic cation transporter Non-inhibitor 0.7886 CYP450 2C9 substrate Non-substrate 0.8231 CYP450 2D6 substrate Non-substrate 0.8041 CYP450 3A4 substrate Non-substrate 0.6473 CYP450 1A2 substrate Non-inhibitor 0.9157 CYP450 2C9 inhibitor Non-inhibitor 0.9147 CYP450 2D6 inhibitor Non-inhibitor 0.9231 CYP450 2C19 inhibitor Non-inhibitor 0.9034 CYP450 3A4 inhibitor Non-inhibitor 0.9471 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8446 Ames test Non AMES toxic 0.6934 Carcinogenicity Non-carcinogens 0.9505 Biodegradation Not ready biodegradable 0.8587 Rat acute toxicity 1.4850 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9728 hERG inhibition (predictor II) Non-inhibitor 0.81
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Targets
- Kind
- Protein
- Organism
- Escherichia coli (strain K12)
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Trna binding
- Specific Function
- With S4 and S5 plays an important role in translational accuracy.Interacts with and stabilizes bases of the 16S rRNA that are involved in tRNA selection in the A site and with the mRNA backbone. Lo...
- Gene Name
- rpsL
- Uniprot ID
- P0A7S3
- Uniprot Name
- 30S ribosomal protein S12
- Molecular Weight
- 13736.995 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Gill AE, Amyes SG: The contribution of a novel ribosomal S12 mutation to aminoglycoside resistance of Escherichia coli mutants. J Chemother. 2004 Aug;16(4):347-9. [Article]
- Eisenstein BI, Beachey EH, Ofek I: Influence of sublethal concentrations of antibiotics on the expression of the mannose-specific ligand of Escherichia coli. Infect Immun. 1980 Apr;28(1):154-9. [Article]
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Roy U, Nair D: Biodiversity of organotin resistant Pseudomonas from west coast of India. Ecotoxicology. 2007 Mar;16(2):253-61. Epub 2006 Nov 28. [Article]
- Wachino J, Shibayama K, Kurokawa H, Kimura K, Yamane K, Suzuki S, Shibata N, Ike Y, Arakawa Y: Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides. Antimicrob Agents Chemother. 2007 Dec;51(12):4401-9. Epub 2007 Sep 17. [Article]
- Brown JM, Cowley KD, Manninen KI, McNeil MM: Phenotypic and molecular epidemiologic evaluation of a Nocardia farcinica mastitis epizootic. Vet Microbiol. 2007 Nov 15;125(1-2):66-72. Epub 2007 May 6. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- General Function
- Phosphatidylinositol phospholipase c activity
- Specific Function
- Senses changes in the extracellular concentration of calcium ions. The activity of this receptor is mediated by a G-protein that activates a phosphatidylinositol-calcium second messenger system.
- Gene Name
- CASR
- Uniprot ID
- P41180
- Uniprot Name
- Extracellular calcium-sensing receptor
- Molecular Weight
- 120672.385 Da
References
- Molostvov G, James S, Fletcher S, Bennett J, Lehnert H, Bland R, Zehnder D: Extracellular calcium-sensing receptor is functionally expressed in human artery. Am J Physiol Renal Physiol. 2007 Sep;293(3):F946-55. Epub 2007 May 30. [Article]
Drug created at June 13, 2005 13:24 / Updated at February 20, 2024 23:54